207_Combined course Presentations

The future drug development paradigm?

Histology and molecular selection

Proof of concept

Safety and tolerability

Substancially efficacy in selected patients uding innovative trial designs and endpoints

Functional target selection

Trial design accounting for interpatient and intratumor heterogeneity

Pharmacology Antitumor activity